Bardet-Biedl Syndrome

Overview

Bardet-Biedl syndrome (BBS) is a rare inherited disorder in which changes in genes needed for the function of primary cilia—microscopic structures that help cells sense and communicate—affect many organs. It is usually inherited in an autosomal-recessive pattern. Common features include progressive retinal degeneration and vision loss, early-onset obesity and intense hunger (hyperphagia), extra fingers or toes, kidney and urinary-tract disease, learning or developmental differences, and reproductive or endocrine abnormalities. Symptoms and severity vary substantially between people, but visual impairment and kidney complications can be life-changing and require lifelong follow-up. European BBS consensus recommendations

There is not yet a cure that corrects BBS throughout the body. Current care is multidisciplinary and focuses on regular retinal, kidney, blood-pressure, metabolic, developmental, and psychosocial monitoring; low-vision support; treatment of diabetes or other complications; and individualized nutrition and behavioral support. Setmelanotide, a drug that activates the melanocortin-4 receptor appetite-regulation pathway, is approved in the United States for long-term weight management in people aged 2 years and older with obesity due to BBS, but it does not repair the underlying genetic defect or reverse retinal degeneration. European BBS consensus recommendations FDA orphan-drug approval record

Scope of Recent Research (2020–present)

Research since 2020 has moved BBS closer to disease-modifying treatment, especially for inherited retinal degeneration, while also improving treatment of hyperphagia and obesity. The central questions are whether replacement of a missing BBS gene can preserve photoreceptors before they die, how early treatment must occur, and whether therapies can eventually address symptoms beyond the eye. As of October 10, 2026, the field has reached a major threshold: AXV-101, a BBS1 gene-replacement therapy, is recruiting in a first-in-human trial, but no intervention has yet demonstrated a whole-body cure for BBS in people. AXIS trial registry

Major Breakthroughs and Emerging Therapies

The leading curative-intent strategy is gene augmentation, meaning delivery of a working copy of a disease gene rather than editing the patient’s DNA. In a BBS10 mouse model, researchers delivered a normal Bbs10 gene beneath the retina using an adeno-associated virus (AAV) vector. Treated eyes showed slower photoreceptor loss, preservation of retinal electrical responses, recovery of cone-cell function, and better performance on vision-guided tasks. This is an important proof of principle because BBS10-associated retinal disease can be severe and because the benefit persisted through much of the animals’ lifespan; however, it remains a mouse study rather than evidence of benefit in people. Subretinal BBS10 gene therapy study

The first clinical gene-therapy program targets BBS1, the most common BBS subtype in many populations. Axovia Therapeutics’ AXV-101 is an AAV9-based, codon-optimized BBS1 gene-replacement candidate designed for subretinal injection. Company-reported preclinical work in Bbs1 M390R mice found dose-related preservation of photoreceptors and the outer nuclear layer, the retinal layer containing photoreceptor cell bodies. These findings are encouraging, but they are preliminary company data and cannot establish safety, durability, or visual benefit in humans. AXV-101 preclinical presentation

A separate disease-modifying direction addresses BBS-related metabolic disease. In a 2025 Bbs5-knockout mouse study, investigators used hypothalamic RNA profiling to identify altered appetite and metabolic signaling, then treated the animals with the GLP-1 receptor agonist semaglutide. The treatment improved food intake, body composition, glucose tolerance, and behavioral measures in that model. This work supports testing precision metabolic therapies in BBS, but it is preclinical and should not be interpreted as evidence that GLP-1 drugs cure BBS or restore ciliary function. Transcriptome-guided GLP-1 therapy in a BBS mouse model

Setmelanotide represents the most established targeted treatment, but it is a symptom-directed therapy rather than a cure. By activating MC4R, a brain pathway involved in satiety and energy balance, it can reduce hunger and improve weight outcomes in some people with BBS. In the pivotal phase 3 program, 32.3% of participants aged 12 years or older with BBS achieved at least 10% weight loss after 52 weeks; skin darkening was the most common treatment-emergent adverse event. Phase 3 setmelanotide trial

Clinical Trials and Experimental Approaches

The most notable curative-intent trial is AXIS, an open-label, first-in-human dose-escalation study of AXV-101 for children aged 4–17 years with biallelic BBS1 variants and progressive retinal degeneration. The recruiting United Kingdom study plans to enroll up to 12 participants, compare the treated eye with the untreated eye, administer a single subretinal dose in two cohorts, and follow participants for five years. Its primary goal is safety and tolerability, not proof of efficacy, so there are no clinical outcomes available yet. AXIS trial registry

Setmelanotide has the strongest completed clinical evidence base in BBS. The randomized phase 3 trial, sponsored by Rhythm Pharmaceuticals, used a 14-week placebo-controlled period followed by open-label treatment to week 52 in participants aged 6 years and older with BBS or Alström syndrome. A later matched comparison of 29 treated people with BBS against 58 participants from the CRIBBS natural-history registry found that 58.6% of treated participants met the study’s age-appropriate weight-response endpoint at week 52, compared with 6.9% of matched usual-care controls; this supports effectiveness for obesity management but does not test vision, kidney disease, or genetic correction. Phase 3 setmelanotide trial 52-week setmelanotide comparison with CRIBBS

A completed phase 3 pediatric study, NCT04966741, evaluated setmelanotide in children aged 2 to under 6 years with rare genetic obesity, including BBS. The registry reports 12 enrolled participants overall and continued follow-up opportunities through a long-term extension for participants likely to benefit. This program helped support the expanded U.S. indication for BBS-associated obesity in children aged 2 years and older. Pediatric setmelanotide trial record FDA orphan-drug approval record

Methodologies and Scientific Approaches

BBS cure research combines genetic diagnosis with disease models that reveal when and where treatment may work. Gene-therapy groups use mouse models carrying specific BBS variants, then assess retinal structure with optical coherence tomography, retinal activity with electroretinography, tissue changes with histology, and vision-related behavior with maze or swim tests. The BBS10 work also used one eye as a treated eye and the other as an internal untreated comparison, an efficient design for early retinal-therapy studies. Subretinal BBS10 gene therapy study

Researchers are also using patient-derived induced pluripotent stem cells (iPSCs), which are adult cells reprogrammed into stem-like cells and then developed into disease-relevant cell types. In one study, iPSC-derived neurons from people with BBS1 M390R or BBS10 frameshift variants showed altered neurite growth, cilia abnormalities, and disrupted signaling, offering a platform to investigate disease mechanisms and screen candidate therapies. Clinical studies add biomarkers such as retinal imaging, visual-function testing, anti-AAV antibody monitoring, and measurement of vector material in blood, urine, and tears. Patient iPSC-derived neuron study AXIS trial registry

Leading Institutions and Funding

Moorfields Eye Hospital and Axovia Therapeutics are leading the clinical translation of BBS1 retinal gene therapy through the AXIS trial, while academic retinal-gene-therapy teams have generated the BBS10 mouse evidence supporting gene augmentation. The BBS Foundation has also supported the Clinical Registry Investigating Bardet-Biedl Syndrome (CRIBBS), an international natural-history registry that has become important for understanding disease progression and for constructing external control groups in rare-disease research. AXIS trial registry Subretinal BBS10 gene therapy study 52-week setmelanotide comparison with CRIBBS

Patient-led organizations are particularly influential because BBS is rare and geographically dispersed. The Bardet Biedl Syndrome Foundation received an $800,000, five-year Chan Zuckerberg Initiative Rare As One Network award announced at the end of 2024 to strengthen patient-centered research networks. A Race Against Blindness reported $5.1 million in cumulative commitments to AXV-101 by early 2026, including grants intended to close funding gaps for the first-in-human study. BBS Foundation funding update A Race Against Blindness funding update

Strengths, Limitations, and Challenges

The strongest recent advance is that BBS retinal gene therapy has progressed from animal rescue experiments to a recruiting human study. Treating the eye offers practical advantages: the subretinal space is localized, the untreated eye can sometimes serve as a comparator, and retinal imaging provides sensitive structural outcome measures. Meanwhile, setmelanotide has established that a pathway-informed medicine can meaningfully reduce hunger and weight burden for some people with BBS. AXIS trial registry 52-week setmelanotide comparison with CRIBBS

The limitations are substantial. BBS is genetically diverse and affects many organs, so a treatment for BBS1-related retinal disease cannot automatically help people with BBS10, BBS5, or other subtypes, nor is a subretinal injection expected to correct kidney disease, developmental differences, or systemic obesity. Gene therapy also must be delivered before too many photoreceptors are lost; the BBS10 mouse study found better rod-and-cone rescue with earlier treatment than with treatment at a later disease stage. AAV treatment can provoke immune responses, requires invasive eye surgery, and must demonstrate long-term safety and durability; AXIS therefore includes steroid prophylaxis, antibody monitoring, and five years of follow-up. Subretinal BBS10 gene therapy study AXIS trial registry

Outlook and Future Directions

BBS is not close to a universal cure, but the outlook is more concrete than it was at the start of this decade. The key milestone to watch is the safety readout from AXIS: acceptable safety, evidence of retinal preservation relative to the untreated eye, and durable benefit would justify larger studies and could validate gene replacement as a platform for additional BBS genes. Parallel priorities are earlier genetic diagnosis, better natural-history data, scalable manufacturing, and strategies that can address non-eye manifestations. For now, the realistic near-term goal is not reversal of established multisystem disease, but preserving vision earlier, reducing the burden of hyperphagia and obesity, and building toward gene-specific treatments that can be tested across the genetically diverse BBS population. AXIS trial registry European BBS consensus recommendations

References

• European BBS consensus recommendations — Dollfus et al., European Journal of Human Genetics, 2024.
• FDA orphan-drug approval record — U.S. Food and Drug Administration, 2024.
• Subretinal BBS10 gene therapy study — Hsu et al., Molecular Therapy: Nucleic Acids, 2023.
• AXV-101 preclinical presentation — Axovia Therapeutics, 2024.
• Transcriptome-guided GLP-1 therapy in a BBS mouse model — Barabino et al., iScience, 2025.
• Phase 3 setmelanotide trial — Haqq et al., The Lancet Diabetes & Endocrinology, 2022.
• 52-week setmelanotide comparison with CRIBBS — Pomeroy et al., Obesity, 2026.
• Pediatric setmelanotide trial record — ClinicalTrials.gov, 2024.
• Patient iPSC-derived neuron study — Wang et al., Stem Cell Reports, 2021.
• AXIS trial registry — ISRCTN Registry, 2026.
• BBS Foundation funding update — Bardet Biedl Syndrome Foundation, 2025.
• A Race Against Blindness funding update — A Race Against Blindness, 2026.